Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCR and 4-1BB Signaling Domains in Patients With Chemotherapy Resistant or Refractory Acute Lymphoblastic Leukemia

Clinical Trial ID NCT02030847

Rank	Title	Journal	Year	PubWeight™‹?›
1	Engineered T cells: the promise and challenges of cancer immunotherapy.	Nat Rev Cancer	2016	1.51
2	Trial Watch: Adoptive cell transfer for anticancer immunotherapy.	Oncoimmunology	2014	0.96
3	CD19-redirected chimeric antigen receptor-modified T cells: a promising immunotherapy for children and adults with B-cell acute lymphoblastic leukemia (ALL).	Ther Adv Hematol	2015	0.95
4	Cell-based strategies to manage leukemia relapse: efficacy and feasibility of immunotherapy approaches.	Leukemia	2014	0.86
5	Trial Watch: Adoptive cell transfer for oncological indications.	Oncoimmunology	2015	0.84
6	Adoptive T-cell therapies for refractory/relapsed leukemia and lymphoma: current strategies and recent advances.	Ther Adv Hematol	2015	0.82
7	Targeting CD8+ T-cell tolerance for cancer immunotherapy.	Immunotherapy	2014	0.81
8	Adoptive immunotherapy for acute leukemia: New insights in chimeric antigen receptors.	World J Stem Cells	2015	0.78
9	Using gene therapy to manipulate the immune system in the fight against B-cell leukemias.	Expert Opin Biol Ther	2015	0.77
10	Chimeric antigen receptors and bispecific antibodies to retarget T cells in pediatric oncology.	Pediatr Blood Cancer	2015	0.75